key: cord-1050668-mzqo4wjo
authors: Yang, C.; Jiang, M.; Wang, X.; Tang, X.; Fang, S.; Li, H.; Zuo, L.; Jiang, Y.; Zhong, Y.; Chen, Q.; Zheng, C.; Wang, L.; Wu, S.; Wu, W.; Liu, H.; Yuan, J.; Liao, X.; Zhang, Z.; Lin, Y.; Geng, Y.; Zhang, H.; Zheng, H.; Wan, M.; Lu, L.; Ren, X.; Cui, Y.; Zou, X.; Feng, T.; Xia, J.; Yang, R.; Liu, Y.; Mei, S.; Li, B.; Yang, Z.; Hu, Q.
title: Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study
date: 2020-07-26
journal: nan
DOI: 10.1101/2020.07.21.20125138
sha: 36f9a09ff8f4fa3376933cca672fb25c2d1657d0
doc_id: 1050668
cord_uid: mzqo4wjo

Background Managing discharged COVID-19 (DC) patients with recurrent positive (RP) SARS-CoV-2 RNA test results is challenging. We aimed to comprehensively characterize the viral RNA level and serum antibody responses in RP-DC patients and evaluate their viral transmission risk. Methods A population-based observational cohort study was performed on 479 DC patients discharged from February 1 to May 5, 2020 in Shenzhen, China. We conducted RT-qPCR, antibody assays, neutralisation assays, virus isolation, whole genome sequencing (WGS), and epidemiological investigation of close contacts. Findings Of 479 DC patients, the 93 (19%) RP individuals, including 36 with multiple RP results, were characterised by young age (median age: 34 years, 95% confidence interval [CI]: 29-38 years). The median discharge-to-RP length was 8 days (95% CI: 7-14 days; maximum: 90 days). After readmission, RP-DC patients exhibited mild (28%) or absent (72%) symptoms, with no disease progression. The viral RNA level in RP-DC patients ranged from 1.9-5.7 log10 copies/mL (median: 3.2, 95% CI: 3.1-3.5). At RP detection, the IgM, IgG, IgA, total antibody, and neutralising antibody (NAb) seropositivity rates in RP-DC patients were 38% (18/48), 98% (47/48), 63% (30/48), 100% (48/48), and 91% (39/43), respectively. Regarding antibody levels, there was no significant difference between RP-DC and non-RP-DC patients. The antibody level remained constant in RP-DC patients pre- and post-RP detection. Virus isolation of nine representative specimens returned negative results. WGS of six specimens yielded only genomic fragments. No clinical symptoms were exhibited by 96 close contacts of 23 RP-DC patients; their viral RNA (96/96) and antibody (20/20) test results were negative. After full recovery, 60% of patients (n=162, 78 no longer RP RP-DC and 84 non-RP-DC) had NAb titres of [≥]1:32. Interpretation RP may occur in DC patients following intermittent and non-stable excretion of low viral RNA levels. RP-DC patients pose a low risk of transmitting SARS-CoV-2. An NAb titre of [≥]1:32 may provide a reference indicator for evaluating humoral responses in COVID-19 vaccine clinical trials.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.21.20125138 doi: medRxiv preprint qPCR. After quarantine, DC patients were regularly followed-up on the 7 th , 14 th , 30 th , and 60 th days 102 post-discharge. Demographic and clinical severity information was extracted from electronic 103 hospital medical records. Clinical severity on first admission was classified as asymptomatic, mild, 104 moderate, or critical based on Chinese Guidelines for Diagnosis and Treatment for Novel 105 Coronavirus Pneumonia 12 . 106

The study was approved by the Ethics Committee of Shenzhen CDC (QS2020060007). As data 108 collection is part of the public health investigation of an emerging outbreak, individual informed 109 consent was waived. 110 111

Because negative results from two consecutive SARS-CoV-2 RNA tests were part of the discharge 113 criteria, a DC patient with recurrent positive test results was defined as an RP-DC patient ( Figure  114 1b and appendix Figure S1 ). These patients were readmitted to hospital for further medical 115 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. 

We performed statistical analyses using R version 3.6.1. Categorical and continuous variables were 144 compared using Chi-squared and Mann-Whitney U tests, respectively. Correlations were assessed 145 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. The funders had no role in study design; data collection, analysis, or interpretation; or report writing. 149

The corresponding authors had full access to all study data and had final responsibility for the 150 decision to submit for publication. 151 Figure S1 ). 164 165 There were more female (57/93, 61%) than male RP-DC patients (36/93, 39%, underlying immunodeficiency diseases, and 14 RP-DC patients (15%) were treated with steroids 171 (methylprednisolone and/or dexamethasone) during hospitalization. There were no significant 172 differences between RP-DC and NRP-DC patients in terms of hospitalization period, clinical 173 severity on first admission, or steroid use (p>0·05). The C-reactive protein (CRP) level of RP-DC 174 patients on first admission was significantly higher than that of NRP-DC patients (p=0·03), but there 175 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. We further quantitatively investigated the RP-DC and NRP-DC patient antibody levels during 220 different sampling periods. Seventy five percent of RP-DC patients were identified during their two-221

week quarantine; no significant differences from NRP-DC patients were identified in specimens 222 from this period (Figure 3a ). During our entire sampling period (3-17 weeks post-disease onset), no 223 significant weekly differences were identified, except the IgM and total antibody level in week 3 224 and IgM level in weeks 6-8 (p<0.05, Figure 3b ). Specifically, one (1%) and five (6%) RP-DC 225 patients were negative for IgG and NAb, respectively, which is not significantly different (p>0·05) 226 from NRP-DC patients (IgG-negative: 3% [3/94]j; Nab-negative: 8% [7/84]). Furthermore, we 227 compared the RP-DC patient antibody levels on the day of RP detection and within one week before 228 and after RP detection (when patients were viral RNA negative); no significant differences were 229 identified ( Figure 3c ). Together, these results indicate that the SARS-CoV-2-specific anti-RBD 230 antibody levels (excluding IgM) are similar in RP-DC and NRP-DC patients and in RP-DC patients 231 regardless of current RP detection. Additionally, there was a significant correlation between NAb 232 titres and antibody levels (R>0·40, p<0·0001), particularly for IgG (R=0·73, p<0·0001) and total 233 antibody (R=0·77, p<0·0001), which indicates that they may be alternative indicators of NAb titre 234 (appendix Figure S4) . 235 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. we found that RP-DC patients accounted for 19% of DC patients, which is close to most previous 291 reports (15%-21%) 7, 9, 10 but much higher than one recent report where 3% (23/651) of RP-DC 292 patients were identified in a routine health check of DC patients. 16 Considering that multiple 293 negative RNA tests were also identified in our RP-DC patients, differences in detected RP-RC 294 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.21.20125138 doi: medRxiv preprint 11 patient proportions may be related to the viral RNA testing frequency. However, in the context of 295 systematic follow-up and testing, RP occurrence in DC patients is unlikely to be rare. 296 297 Although RP-DC patients have been observed by multiple independent researchers 6-10 and 298 government authorities, including the Korean CDC, 17 the cause of RP occurrence remains unclear, 299 and several hypotheses have been proposed. 1) RP might be due to false-negative SARS-CoV-2 300 RNA test results at discharge. 9, 18 Here, in the 59% of RP-DC patients who had additional negative 301 test results before their first RP result, the sampling and testing were performed by the same 302 technician using the same kits, minimizing the likelihood of false-negative results. 2) RP could be 303 due to post-discharge reinfection. Here, 75% of RP-DC patients were identified during quarantine, 304 and those identified during follow-up did not report any contact with COVID-19 patients, making 305 reinfection unlikely. 3) In people with low antibody levels or immunity, uneradicated virus could 306 cause secondary infections. 19 We did not detect significant differences in antibody levels between 307 RP-DC and NRP-DC patients or in RP-DC patients over time, suggesting that humoral immunity 308 may not be related to RP occurrence. Additionally, none of the RP-DC patients had 309 immunodeficiency diseases, and there was no significant difference in steroid treatment between 310 RP-DC and NRP-DC patients. However, more data are needed to verify the relationship between 311 RP occurrence and immunity, especially regarding cellular immunity. 4) RP occurrence may be 312 due to the shedding of 'dead' virus particles. This possibility is consistent with our negative virus 313 isolation results. However, failed viral isolation does not confirm a lack of live virus; Wölfel and 314 colleagues 20 found that live virus cannot be successfully isolated when the viral load is below 10 6 315 copies/mL. More sensitive live virus detection methods, such as identification of subgenomic 316 messenger RNA 20 , are needed to prove this hypothesis. Based on our data from SARS-CoV-2 317 RNA testing on 2,589 clinical samples collected from February 18 to May 5, eleven RP-RC 318 patients were identified ≥30 days post-discharge (maximum: 90 days post-discharge), and all 319 patients had recovered; therefore, we propose that RP occurrence in DC patients is due to their 320 intermittent and non-stable excretion of low levels of viral RNA. However, further studies on the 321 mechanism of RP occurrence are needed. 322 323 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. CoV-2 RNA test results, and 20 of them had negative antibody results, suggesting there were no 353 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.21.20125138 doi: medRxiv preprint 

A novel coronavirus from patients with pneumonia in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: 425 implications for virus origins and receptor binding

Clinical Characteristics of Coronavirus Disease 2019 in China

Coronavirus disease (COVID-2019) situation reports

COVID-19): A Review

Positive RT-PCR test results in patients recovered from COVID-19

Clinical characteristics of the recovered COVID-19 patients with re-435 detectable positive RNA test

Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report. 437 International journal of infectious diseases : IJID : official publication of the International Society for 438

False-negative of RT-PCR and prolonged nucleic acid conversion in 16

Factors associated with prolonged viral RNA shedding in patients with 451 COVID-19

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. The 453 lancet

Assessment of patients who tested positive for COVID-19 after 455 recovery

Findings from investigation and analysis of re-positive cases

Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients 459 clinically diagnosed with COVID-19

The Dynamic Changes of Antibodies against SARS-CoV-2 during the 461 Infection and Recovery of COVID-19

Virological assessment of hospitalized patients with 463 COVID-2019

Genomic Epidemiology of SARS-CoV-2 in Guangdong Province

Detection of SARS-CoV-2-specific humoral and cellular immunity in 467 COVID-19 convalescent individuals

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 469 recovered patient cohort and their implications

SARS-CoV-2 vaccines: status report

Safety, tolerability, and immunogenicity of a recombinant 472 adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-473 human trial

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Our study has several limitations. First, this was a single-centre study conducted on all DC 373 patients from Shenzhen. Because there are differences in the discharge criteria and SARS-CoV-2 374 RNA testing methods among different cities and counties, our RP incidence needs to be verified 375 by multicentre studies. Second, we collected only nasopharyngeal swab, anal swab, and serum 376 specimens based on current sampling policies; other specimen types with generally higher viral 377 loads, such as lower respiratory tract and sputum specimens, were not collected. Thus, the RP 378 incidence in this study represents a conservative estimation. Third, the systemic collection of 379 serum specimens started mid-study, and serum specimens from RP-DC patients during their 380 hospitalization were not available, which limited further investigations on the antibody level 381 dynamics of RP-DC patients. Finally, due to the strict management of DC patients, most DC 382 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.21.20125138 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.21.20125138 doi: medRxiv preprint